GlassScriptPhysician profile
Remia Paduga
NPI 1194933853
$4,679.73
in general payments reported to CMS, 2019-2025
33 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $536 · 2021: $888 · 2022: $380 · 2023: $335 · 2024: $545 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,281.61 | 2019-2022 | |
| Ucb, INC. | $753.91 | 2022-2025 | Nayzilam, Fintepla, Zilbrysq |
| Penumbra, INC. | $276.38 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $255.33 | 2019-2023 | Ultomiris |
| Abbvie INC. | $234.48 | 2022-2025 | |
| Allergan, INC. | $229.97 | 2020-2021 | |
| Medtronic Vascular, INC. | $223.01 | 2019 | |
| Chiesi USA, INC. | $141.07 | 2023 | Cleviprex, Kengreal |
| Amgen INC. | $132.17 | 2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $124.99 | 2025 | Ponvory |
| Csl Behring | $124.12 | 2024 | Hizentra |
| Horizon Therapeutics Plc | $100.97 | 2021 | |
| Impel Pharmaceuticals INC. | $92.35 | 2022 | |
| Biogen, INC. | $74.82 | 2019-2024 | Spinraza, Qalsody |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $48.38 | 2019 | |
| Genzyme Corporation | $45.73 | 2021 | |
| Neuronetics, INC. | $40.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $37.97 | 2021 | |
| Emd Serono, INC. | $35.99 | 2019 | |
| Lilly USA, LLC | $35.72 | 2024 | Kisunla, Reyvow, Emgality |
| Astrazeneca Pharmaceuticals LP | $35.23 | 2021 | |
| Lundbeck LLC | $32.72 | 2019-2024 | Vyepti |
| Ceribell, INC. | $28.61 | 2023 | Ceribell Rapid Response Eeg |
| Avanir Pharmaceuticals, INC. | $22.73 | 2022 | |
| Abbott Laboratories | $20.54 | 2022 | |
| Adamas Pharmaceuticals, INC. | $20.30 | 2020 | |
| Neurocrine Biosciences, INC. | $19.72 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $18.57 | 2025 | Lumryz |
| Microtransponder, INC. | $18.52 | 2025 | |
| Medtronic USA, INC. | $16.83 | 2019 | |
| Currax Pharmaceuticals LLC | $16.49 | 2021 | |
| Sk Life Science, INC. | $15.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remia Paduga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.